Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert